Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

Abstracts: Objective: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. Methods: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng-Di Liu, Rong Zhao, Xue-Mei Wang, Shuo Wang, Xiao-Lei Shen, Xiao-Xiao Tao, Bo Zheng, Jia-Li Peng, Hui Zhang, Ran Mo, Yan Tong, Wen-Ting Li, Xiao-Yan Feng, Ge-Fei Li, Liang Shu, Jian-Ren Liu
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/118a427805ec498eb9fa0c460219d6ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:118a427805ec498eb9fa0c460219d6ea
record_format	dspace
spelling	oai:doaj.org-article:118a427805ec498eb9fa0c460219d6ea2021-12-02T11:50:03ZDoes novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai2095-882X10.1016/j.cdtm.2015.11.005https://doaj.org/article/118a427805ec498eb9fa0c460219d6ea2015-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X15000717https://doaj.org/toc/2095-882XAbstracts: Objective: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. Methods: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. Patients: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. Results: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. Conclusion: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance. Keywords: Dabigatran etexilate, Novel oral anticoagulant, Cardiogenic cerebral embolism, Non-valvular atrial fibrillation, Real-world studyFeng-Di LiuRong ZhaoXue-Mei WangShuo WangXiao-Lei ShenXiao-Xiao TaoBo ZhengJia-Li PengHui ZhangRan MoYan TongWen-Ting LiXiao-Yan FengGe-Fei LiLiang ShuJian-Ren LiuKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 1, Iss 4, Pp 203-209 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Feng-Di Liu Rong Zhao Xue-Mei Wang Shuo Wang Xiao-Lei Shen Xiao-Xiao Tao Bo Zheng Jia-Li Peng Hui Zhang Ran Mo Yan Tong Wen-Ting Li Xiao-Yan Feng Ge-Fei Li Liang Shu Jian-Ren Liu Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
description	Abstracts: Objective: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. Methods: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed. Patients: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. Results: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE. Conclusion: The use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance. Keywords: Dabigatran etexilate, Novel oral anticoagulant, Cardiogenic cerebral embolism, Non-valvular atrial fibrillation, Real-world study
format	article
author	Feng-Di Liu Rong Zhao Xue-Mei Wang Shuo Wang Xiao-Lei Shen Xiao-Xiao Tao Bo Zheng Jia-Li Peng Hui Zhang Ran Mo Yan Tong Wen-Ting Li Xiao-Yan Feng Ge-Fei Li Liang Shu Jian-Ren Liu
author_facet	Feng-Di Liu Rong Zhao Xue-Mei Wang Shuo Wang Xiao-Lei Shen Xiao-Xiao Tao Bo Zheng Jia-Li Peng Hui Zhang Ran Mo Yan Tong Wen-Ting Li Xiao-Yan Feng Ge-Fei Li Liang Shu Jian-Ren Liu
author_sort	Feng-Di Liu
title	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_short	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_full	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_fullStr	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_full_unstemmed	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
title_sort	does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: an inpatient registration study in shanghai
publisher	KeAi Communications Co., Ltd.
publishDate	2015
url	https://doaj.org/article/118a427805ec498eb9fa0c460219d6ea
work_keys_str_mv	AT fengdiliu doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT rongzhao doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT xuemeiwang doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT shuowang doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT xiaoleishen doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT xiaoxiaotao doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT bozheng doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT jialipeng doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT huizhang doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT ranmo doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT yantong doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT wentingli doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT xiaoyanfeng doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT gefeili doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT liangshu doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai AT jianrenliu doesnoveloralanticoagulantimproveanticoagulationfornonvalvularatrialfibrillationassociatedstrokeaninpatientregistrationstudyinshanghai
_version_	1718395148650414080

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

Ejemplares similares